GLP-1 Agonists Show Promise in Preventing Life-Threatening Heart Arrhythmias
Background
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs), such as semaglutide and liraglutide, are well-established for their efficacy in treating type 2 diabetes and obesity, and have demonstrated broader cardiovascular benefits. While their positive impact on heart health is recognized, their direct role and underlying mechanisms in preventing or treating cardiac arrhythmias—irregular heartbeats that can be life-threatening—remain underexplored. This study aimed to investigate the potential antiarrhythmic properties of GLP-1RAs and elucidate their protective mechanisms.
Results
The study revealed significant and dose-dependent antiarrhythmic effects of liraglutide. In the I/R control group, 100% of rats developed ventricular tachycardia (VT) and 80% experienced ventricular fibrillation (VF), leading to a high 60% mortality rate within the reperfusion period. The lower dose of liraglutide (0.1 mg/kg) reduced VT incidence to 65% and VF to 40%, with mortality at 30%. Treatment with liraglutide at 0.3 mg/kg significantly reduced the incidence of VT to 25% (p<0.001) and VF to 10% (p<0.001) compared to the control group, while also decreasing mortality to 15% (p<0.01). Furthermore, the total duration of VT was reduced by 75% and VF by 85% in the high-dose group. Mechanistically, liraglutide treatment led to a 2.3-fold increase in myocardial cAMP levels and a 1.8-fold reduction in oxidative stress markers, suggesting improved cellular energy metabolism and reduced myocardial damage.
Why It Matters
This research provides compelling evidence that GLP-1RAs possess direct antiarrhythmic properties, significantly extending their known cardiovascular benefits beyond glycemic control and weight loss. The observed substantial reduction in severe arrhythmias and associated mortality suggests a novel therapeutic application for these widely used drugs. If these promising findings translate to humans, GLP-1RAs could become a valuable adjunct therapy for patients at high risk of cardiac arrhythmias, particularly those with underlying cardiovascular disease or post-ischemic injury. Future steps should involve exploring these mechanisms in larger animal models and eventually in Phase II human trials specifically focusing on arrhythmia endpoints.